

Table 1: Patients' characteristics

Number of patients	150
Gender F/M (%)	56 (37.3) / 94 (62.7)
Median age (range), years	64 (16-80)
Hematological malignancies, N (%)	
DLBCL	112 (74.7)
FL	11 (7.3)
MCL	11 (7.3)
ALL	9 (6)
MM	7 (4.7)
CAR-T cells type, N (%)	
axicabtagene ciloleucel	90 (60)
tisagenlecleucel	34 (22.6)
brexucabtagene autoleucel	10 (6.7)
clinical Trials	9 (6)
idecabtagene vicleucel	7 (4.7)
Disease status before infusion, N (%)	
Complete response	11 (7.3)
Partial response	47 (31.3]
Progressive disease	67 (44.7)
Stable disease	25 (16.7)
Prior lines, N (%)	
1	14 (9.3)
2	86 (57.3)
3	36 (24.1)
≥4	14 (9.3)
Prior auto-HSCT, N (%)	33 (22)
Prior allo-HSCT, N (%)	9 (6)

DLBCL : diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; ALL: acute lymphoblastic lymphoma; MM: multiple myeloma, HSCT: hematopoietic stem cell transplantation.